Elismetrep clinical trials
Also written MT-8554.
How each study uses elismetrep is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the elismetrep studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
14 studies that test it; most in 2017 (3)
| Year | Studies |
|---|---|
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 3 |
| 2018 | 2 |
| 2021 | 1 |
| 2025 | 1 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 14 · Other 0
Tanabe Pharma Corporation (6) · TriGemX Bio, Inc. (4) · Tanabe Pharma America, Inc. (4)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 2 in phase 3
Studies that test elismetrep, phase 3 first.
- Feb 2027A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of MigrainePhase 3 · TriGemX Bio, Inc.
- Oct 2027A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of MigrainePhase 3 · TriGemX Bio, Inc.
Studies
Open first, then newest update. How each study uses elismetrep is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 14
- A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of MigraineRecruitingPhase 3TriGemX Bio, Inc.NCT07816367Written as Elismetrep
- A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of MigraineRecruitingPhase 3TriGemX Bio, Inc.NCT07674654Written as Elismetrep
- A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of MigraineRecruitingPhase 3TriGemX Bio, Inc.NCT07645924Written as Elismetrep
- A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of MigraineCompletedPhase 2TriGemX Bio, Inc.NCT06848075Written as Elismetrep (K-304) 2 mg
- MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal WomenCompletedPhase 2Tanabe Pharma America, Inc.NCT03291067Written as MT-8554 1mg
- Long-term Safety and Efficacy Study of MT-8554 in Postmenopausal Women With Vasomotor SymptomsCompletedPhase 2Tanabe Pharma America, Inc.NCT03541200Written as MT-8554
- A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of MT-8554 in Female Subjects Experiencing Vasomotor SymptomsCompletedPhase 1Tanabe Pharma CorporationNCT02803268Written as MT-8554 low dose
- Exploratory Study of MT-8554 in Subjects With Painful Diabetic Peripheral NeuropathyCompletedPhase 2Tanabe Pharma CorporationNCT05123196Written as MT-8554
- A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-8554 in Healthy SubjectsCompletedPhase 1Tanabe Pharma CorporationNCT02429102Written as MT-8554
- A Study to Investigate the Pharmacodynamic Effect of Single Doses of MT-8554 in Healthy SubjectsCompletedPhase 1Tanabe Pharma CorporationNCT02536209Written as MT-8554 low dose
- A Study to Investigate the Effect of MT-8554 on the Pharmacokinetics of Simvastatin and Rosuvastatin in Healthy SubjectsCompletedPhase 1Tanabe Pharma CorporationNCT02675309Written as MT-8554
- Study to Assess the Efficacy, Safety and Tolerability of MT- 8554 in Subjects With Painful Diabetic Peripheral NeuropathyCompletedPhase 2Tanabe Pharma CorporationNCT03172598Written as MT-8554 low dose
- Definitive QT Study With MT-8554CompletedPhase 1Tanabe Pharma America, Inc.NCT03471130Written as MT-8554 Low dose
- Mass Balance Study With MT-8554CompletedPhase 1Tanabe Pharma America, Inc.NCT03381404Written as [14C] MT-8554
Codes
What other systems call elismetrep · ClinicalTrials.gg INT017070
- UNII (FDA) KIB8V5UR7DELISMETREPOne source FDA
- NCI Thesaurus C169937ElismetrepOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | KIB8V5UR7D | ELISMETREP | One source FDA |
| NCI Thesaurus | C169937 | Elismetrep | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.